Impact of renin–angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: a retrospective observational study

Autor: Yanjun Zhong, Lishu Zhao, Guobao Wu, Chunhong Hu, Chenfang Wu, Min Xu, Haiyun Dong, Quan Zhang, Guyi Wang, Bo Yu, Jianlei Lv, Chao Wu, Siye Zhang, Chenghui Cao, Long Shu, Yue Pan, Xianling Liu, Fang Wu
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Journal of International Medical Research, Vol 48 (2020)
Druh dokumentu: article
ISSN: 1473-2300
03000605
DOI: 10.1177/0300060520979151
Popis: Objective Association of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) use with coronavirus disease 2019 (COVID-19) remains controversial. We aimed to investigate the impact of ACEI/ARB use on all-cause mortality in severe COVID-19 patients with hypertension. Methods We enrolled 650 COVID-19 patients from Changsha and Wuhan city between 17 January 2020 and 8 March 2020. Demographic, clinical characteristics, and outcomes were collected. Multivariable analysis and propensity-score matching were performed to assess the impact of ACEI/ARB therapy on mortality. Results Among the 650 patients, 126 who had severe COVID-19 concomitant with hypertension were analyzed. The average age was 66 years and 56 (44.4%) were men. There were 37 ACEI/ARB users and 21 in-hospital deaths (mortality rate, 16.7%). Male sex (odds ratio [OR], 5.13; 95% confidence interval [CI], 1.75 to 17.8), but not ACEI/ARB use (OR, 1.09; 95%CI, 0.31 to 3.43), was an independent risk factor for mortality in severe COVID-19 patients with hypertension. After propensity-score matching, 60 severe COVID-19 patients were included and no significant correlation between use of ACEI/ARB and mortality was observed. Conclusions There was no significant association of ACEI/ARB use with mortality in severe COVID-19 patients with hypertension. These findings support the continuation of ACEI/ARB therapy for such patients.
Databáze: Directory of Open Access Journals
Externí odkaz: